As per our report, the Asia Pacific Immunotherapy Drugs Market size is estimated to worth USD 23.72 billion by 2026 and USD 13.16 billion in 2021, growing at a tremendous CAGR of 12.5% from 2021 to 2026.
One of the significant factors boosting the APAC immunotherapy drugs market is the increasing patient populations in India and China. In addition, Asia-Pacific is among the major markets with huge market potential due to the rising incidence of cancer, growth in per capita income in many countries like India and China, government initiatives aimed at improving the healthcare sector, and the concentration of major market players to expand their presence in emerging Asia-Pacific countries.
The growing population of female patients suffering from different types of cancer such as lung cancer, breast cancer, ovarian cancer, and other cancers is driving the global cancer immunotherapy market. Moreover, the growth of the geriatric population and the government's contribution to healthcare expenditure are other factors contributing to the growth of the market.
Several factors, including population growth, aging, environmental pollution, and poor eating habits. In addition, smoking, in particular, also remained prevalent in the Asia-Pacific region. Therefore, the increasing prevalence of cancer contributes to the growth of the market during the forecast period. The growth of this market is also attributed to the increasing prevalence of the target diseases, increasing demand for monoclonal antibodies and biological smears, increased adoption of immunotherapy drugs compared to conventional treatments, and a scenario of approval.
Biotechnology techniques are likely to create advanced opportunities for market growth during the forecast period. Furthermore, with the ongoing pandemic situation, most research facilities are funded by the government to have more potent drugs with fewer side effects.
The side effects of these drugs, issues with scheduling and manufacturing complexities, and a high attrition rate in the product development cycle will hamper the proliferation of the APAC immunotherapy drugs market.
The increase in product availability is a major challenge for this market due to strict screening laws. In addition, immunotherapy treatment is considered very expensive by ordinary people. The availability of other forms of treatment is seen as a major challenge for the growth of the immunotherapy drug market.
This research report on the Asia Pacific Immunotherapy Drugs Market has been segmented and sub-segmented into the following categories:
By Drug Type:
The APAC region is the fastest-growing region in the global immunotherapy drugs market. The main reason for this development in the APAC region can be attributed to a low manufacturing cost and an easier regulatory scenario. China and India are the major contributors to the cancer immunotherapy market in Asia-Pacific.
During the forecast period, the Indian immunotherapy drugs market is estimated to grow at the highest CAGR. According to NCIP, 0.33 million people in India have cancer, which keeps increasing due to changing lifestyles. In addition, the presence of a large patient population and increased government support for research and development will drive market growth in India.
The Chinese immunotherapy drugs market is another lucrative regional market in the APAC market. China is the second-largest market for the cancer immunotherapy market, followed by Japan. Increased government support, the rapidly developing economy, and increased healthcare spending will drive growth in the Chinese and Japanese markets. In addition, the availability of highly trained healthcare professionals and the growing acceptance of these therapies, and the growing demand for the treatment have resulted in the growth of the market in these countries.
Australia and the rest of Asia-Pacific account for the smallest market share.
KEY MARKET PLAYERS:
A few of the promising companies operating in the Asia Pacific Immunotherapy Drugs Market profiled in this report are Roche, Merck, Eli Lilly, Novartis, AstraZeneca, GlaxoSmithKline PLC, Amgen, Celgene, Bristol Myers Squibb, and Seattle Genetics.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Drug Type
5.1.1 Monoclonal Antibodies
5.1.5 Checkpoint Inhibitors
5.2 By Application
5.2.1 Blood Cancer
5.2.2 Cervical Cancer
5.2.3 Breast Cancer
5.2.5 Lung Cancer
5.2.6 Gastric Cancer
5.2.7 Prostate Cancer
6. Geographical Analysis
6.5 South Korea
7. Pipeline Product Analysis
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 Eli Lilly
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.8 Bristol Myers Squibb
9.9 GlaxoSmithKline PLC
9.10 Seattle Genetics
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures